Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease
March 28, 2017 vol. 88 no. 13 1273-1281
Gregory S. Day, MD, MSc, Tae Sung Lim, MD, PhD, Jason Hassenstab, PhD, Alison M. Goate, PhD, Elizabeth A. Grant, PhD, Catherine M. Roe, PhD, Nigel J. Cairns, PhD, FRCPath and John C. Morris, MD
Objective: To identify clinical features that reliably differentiate individuals with cognitive impairment due to corticobasal degeneration (CBD) and Alzheimer disease (AD).
Methods: Clinical features were compared between individuals with autopsy-proven CBD (n = 17) and AD (n = 16). All individuals presented with prominent cognitive complaints and were evaluated annually with semistructured interviews, detailed neurologic examinations, and neuropsychological testing.